|Bid||81.00 x 100|
|Ask||87.87 x 100|
|Day's Range||86.07 - 86.84|
|52 Week Range||67.54 - 89.09|
|PE Ratio (TTM)||41.25|
|Forward Dividend & Yield||2.08 (2.41%)|
|1y Target Est||N/A|
Eli Lilly and Co. said Monday its board approved an 8% hike in its quarterly dividend. The drugmaker said it will pay a 56.25 cents a share dividend in the first quarter to shareholders of record as of ...
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.
The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...
In 3Q17, Eli Lilly's (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.
In 3Q17, Eli Lilly's (LLY) Cyramza generated revenues of $196 million, which reflected ~23% growth on a YoY basis and 5% growth on a quarter-over-quarter basis.
Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a gastric cancer treatment met the main goal of preventing the disease from advancing, but failed its secondary target of improving overall survival rates. The company said it would not seek a regulatory approval based on the results. The study tested Cyramza in combination with other drugs as a first-line treatment for patients with advanced forms of gastric cancer, which is estimated to result in the deaths of nearly 11,000 people in the United States this year.
Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a treatment for a type of gastric cancer met its main goal of preventing the disease from advancing. However the trial failed ...
In 3Q17, Eli Lilly's (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.
In 3Q17, Eli Lilly’s (LLY) Forteo generated revenues of $441.7 million, ~13% growth on a year-over-year (or YoY) basis and a 1% decline on a quarter-over-quarter basis.
In 3Q17, Eli Lilly’s (LLY) Adcirca generated revenues of $25.4 million, a ~14% increase on a year-over-year (or YoY) basis and 11% growth on a quarter-over-quarter basis.
Examining how Eli Lilly and Company (NYSE:LLY) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple senseRead More...
TRENTON, N.J. (AP) — U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight.
23 analysts were tracking Pfizer in November 2017. One analyst recommended a “strong buy,” while 11 analysts recommended a “buy.”
Lilly (LLY) announced the label expansion of its psoriasis drug, Taltz, for the active psoriatic arthritis indication in the United States.
As of November 22, 2017, of the 22 analysts tracking Eli Lilly stock, 13 recommend a “buy,” while eight recommend a “hold,” and one recommends a “sell.”
In 3Q17, Eli Lilly surpassed the analysts’ estimates for EPS (earnings per share) and revenues, reporting EPS of $1.05 on revenues of ~$5.7 billion.